🇺🇸 FDA
Pipeline program

Zanubrutinib

IHBDH-IIT20230711

Phase 2 small_molecule active

Quick answer

Zanubrutinib for Refractory/Relapsed Autoimmune Hemolytic Anemia is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Refractory/Relapsed Autoimmune Hemolytic Anemia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials